A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder

In brief

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).

Key facts

Study ID
NCT07172516
Run by
Xenon Pharmaceuticals Inc.
People needed
400
Starts
2025-08-08
Expected to finish
2028-08-01
Last updated by the study team
2026-06-03

Who can join

Age: 18 and older, up to 74. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.